Search results
145 Results for 'Genome Engineering'
- Technologies (11)
- Collaborations (0)
- Team (0)
- News (106)
- Pages (0)
- Multimedia (28)
- Publications (0)
- Jobs (0)
- Events (0)
Technologies 11
-
Ichor: Reversing Aging
Ichor is addressing multiple age-related diseases by identifying genetic interventions that reprogram old cells to a younger state. Therapies based on these interventions could improve survival for cancer patients and long-term cardiovascular and neurological health. -
Plastivores: Plastic-Degrading Super-Microbes and Enzymes
The Plastic Degradation project identifies microbes from natural sources that have a low-level ability to degrade multiple types of plastic. In the laboratory, with the help of synthetic biology, those microbes then are evolved into much more effective plastic-eating microbes that, in the future, could be globally deployed to decompose plastic waste. -
HarborSite: Precise and Efficient Gene Editing for Next-Generation Gene Therapies
The HarborSite next-generation gene therapy platform enables integration of therapeutic genes into genomic safe harbors using highly specific and efficient recombinases to enable more predictable, safe and durable gene therapies. -
CogniXense for Rare Disease Drug Discovery
Unravel Biosciences has licensed a Wyss drug discovery platform technology to identify and create drugs to treat complex central nervous system disorders, starting with Rett syndrome. -
Biotechnology for Conservation and De-Extinction
Colossal Biosciences is leveraging a suite of technologies including genome engineering to de-extinct critical species like the wooly mammoth to advance conservation to combat biodiversity loss. -
SomaCode: Getting Cell Therapies Where They Need to Go
SomaCode is solving the problem of cell therapy delivery by identifying unique molecular “zip codes” for disease and engineering cells to home to those zip codes, making cell therapies safer and more effective.
News 106
Multimedia 28
-
Video/AnimationGeorge Church on Widespread Genomic Sequencing, Xenotransplantation, and Shepherding ChangeIn this interview, GenomeWeb speaks to Core Faculty member George Church, Ph.D., who is also a professor at Harvard Medical School and the Harvard-MIT Program in Health Sciences and Technology. A thinker, inventor, and collaborator extraordinaire, Church’s technologies and personality catalyzed the Human Genome Project, the Personal Genome Project, and more than 50 biotech startups,... -
Video/AnimationGeorge Church: Embracing Outliers in Science and in LifeGeorge Church, Ph.D., is a Core Faculty member at the Wyss Institute and a genetics professor at Harvard Medical School. He is a pioneer in synthetic biology and personalized genomics. In 2017, Time magazine named him as one of the 100 most influential people in the world. In addition to being a scientist, Church is...
-
Video/AnimationThe End of Aging—And Extinction | George Church, Ph.D. on Longevity, Dire Wolves, and Woolly MammothsWhat if aging was optional—and extinction reversible? In this episode of Ignition Sequence, Wyss Core Faculty member and geneticist and biotech pioneer, George Church, Ph.D., joins host Dylan Bohbot to explore the frontiers of gene therapy, de-extinction, and the future of human health. A founding scientist behind the Human Genome Project, and co-founder of Colossal... -
Video/AnimationThe Dish Live with special guest George ChurchIn this very special live taping of “The Dish,” host Johannes Fruehauf sits down with renowned geneticist and Wyss Core Faculty member, George Church, Ph.D. Widely known for discovering the first direct genomic sequencing method, Church has reshaped the world of genetics. A professor at Harvard and MIT and a founding professor at the Wyss...
-
Audio/PodcastSeqVerify: A New Easily Accessible Tool for Comprehensive Cell Line Quality Assessment – The Stem Cell ReportDuring the last decade, advances in genome editing and pluripotent stem cell (PSC) culture have let researchers generate edited PSC lines to study a wide variety of biological questions. However, abnormalities in cell lines such as aneuploidy, mutations, on-target and off-target editing errors, and microbial contamination can arise during PSC culture or due to undesired... -
Video/AnimationHarborSite AnimationThis animation explains how the Wyss Institute’s HarborSite genome editing technology uses highly specific and efficient recombinase enzymes and genomic safe harbors to achieve more predictable, safe, and durable gene therapies. Credit: Wyss Institute at Harvard University